Gadovist®

Gadovist®1.0

High relaxivity1 and established safety profile3-6 due to macrocyclic structure2

Gadovist 15ml
Gadovist Syringe 5ml

Gadovist®1.0 is a macrocyclic agent belonging to the class with high kinetic stability and its macrocyclic structure contributes to a very good safety profile.5-6. The active ingredient in Gadovist® 1.0 is gadobutrol. Gadobutrol contains gadolinium (Gd3+) which is firmly bound in a macrocyclic complex. Gadolinium is a rare earth element, which causes contrast enhancement in MRI scans. Gadovist® 1.0 has higher gadolinium concentration (1.0 mol/L) than all the other marketed extracellular gadolinium-based contrast agents (0.5M). High concentration and high relaxivity1 result in the highest T1 shortening per mL, thus resulting in excellent image quality.2*

How is Gadovist®  1.0 administered?

Gadovist® 1.0 is injected intravenously as a bolus, preferably via an MR power injector.

Indications7

This medicinal product is for diagnostic use only.Gadovist 1.0 is indicated in adults and children including full-term new borns for:

  • Contrast enhancement in cranial and spinal magnetic resonance imaging (MRI)
  • Contrast enhancement in whole body MRI including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system
  • Use in first–pass MRI studies of cerebral perfusion (see section 4.4 Special Warnings and Precautions for Use)
  • Contrast enhancement in magnetic resonance angiography (CE MRA) (see section 5.1 Clinical Trials)
  • Contrast enhancement in cardiac MRI including assessment of rest and pharmacological stress perfusion and delayed enhancement.
011_Image-Highlight_Gadovist

* data from in vitro studies and may not necessarily predict clinical effects

Relaxivity

Relaxivity is a measure of the ability for a gadolinium-based contrast agent (GBCA) to enhance signal intensity on the magnetic resonance (MR) image and is a prerequisite of technical efficacy of GBCAs1. The effect of a gadolinium-based contrast agent (GBCA) to generate contrast mainly depends on its concentration in the local tissue and relaxivity1*

Relaxivity

Signal enhancement by contrast media. The contrast agent only entered tissue A but did not enter tissue B. 3

Adapted from Schild HH. MRI Made Easy... well almost
[iOS App]. Version 1.5.1, Utrecht, The Netherlands: Best Apps
BV; 2018 last accessed 15 September 2020

High relaxivity can be generated by additional hydroxy groups leading to better interaction with bulk water and higher exchange rates.

T1 relaxivity

*The data presented is in vitro and may not necessarily predict clinical effects.

Gadovist Image Szomolanyi 2019

Szomolanyi et al showed that the relaxivity of Gadovist® 1.0 is significantly higher compared to gadoteridol and gadoterate meglumine in plasma and human whole blood1

Relaxivity video

Gadovist

YYMMDD Author/Uploaded by
  1. Szomolanyi P, Rohrer M, Frenzel T, et al Invest Radiol 2019; 54(9):559-564
  2. Frenzel T, Lengsfeld P, Schirmer H et al. Invest Radiol. 2008;43(12):817–28.
  3. Michaely HJ, Aschauer M, Deutschmann H, et al. Invest Radiol. 2017;52(1):55–60.
  4. Endrikat J, Vogtlaender K, Dohanish S, et al. Invest Radiol. 2016;51(9):537–43.
  5. Glutig K, Bhargava R, Hahn G, et al. Pediatr Radiol. 2016;46(9):1317–23.
  6. Prince MR, Lee HG, Lee CH, et al. Eur Radiol. 2017;27(1):286–95.
  7. Gadovist® 1.0 Product Information 12 Feb 2020

PBS Information: This product is not listed on the PBS

GADOVIST® 1.0 [gadobutrol 1.0 mmol/mL]

Please review the full Product Information before prescribing. Approved PI available at
https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-01911-3&d=201909241016933 or upon request from
Bayer Australia Ltd, ABN 22 000 138 714, 875 Pacific Highway, Pymble NSW 2073, phone 1800 008 757. 
® Registered trademark of the Bayer Group, Germany.

Related Products